SAN LUIS OBISPO, California – July 22, 2003 – FzioMed, Inc. announced today that it has relocated and expanded its corporate headquarters in San Luis Obispo, California.
FzioMed’s newly constructed facility includes larger areas for clean room manufacturing of the company’s Oxiplex® products, expanded research and clinical trial management activities, and administrative offices.
“FzioMed is growing rapidly and the new facility secures our ability to meet the demand for multiple Oxiplex product lines,” said Ronald Haynes, President and CEO of FzioMed, Inc. “Sales of our adhesion prevention gel for spine surgery continue to grow outside the U.S. and our clinical trials have expanded. In addition, our new R&D laboratories will allow us to accelerate Oxiplex technology into applications beyond adhesion prevention.”
FzioMed’s new address is:
231 Bonetti Drive
San Luis Obispo, California 93401 USA
FzioMed is a privately held biomedical company engaged in the development and commercialization of advanced, absorbable biosurgery products based on the company’s patented Oxiplex® platform technology. Oxiplex® is an innovative polymer material that is formulated for a variety of surgical indications and markets. Products include those for the prevention of post-surgical adhesions, drug delivery and hemostasis. FzioMed products are at various stages of clinical and pre-clinical development, and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.